We are interested in whole-body radiomics for stratification of patients with different types of lymphoma using Fluorodeoxyglucose PET/CT scans. In particular, we have contributed to the validation of the prognostic value of a simple radiomic biomarker, the total metabolically active tumour volume (TMTV). In addition, we introduced a completely original biomarker that reflects the dissemination of the disease, and showed not only its prognostic value, but also its complementarity with TMTV. We are validating methods for the automatic calculation of these prognostic biomarkers and are seeking to complete them in order to improve the quality of the stratification.

People involved in the laboratory: Anne-Ségolène Cottereau (MD, PhD student in science), Louis Rebaud (PhD student), Kibrom Girum (post-doctoral student), Christophe Nioche, Irène Buvat

The work is partly supported by Siemens Healthineers and by the EU as part of the HOLY2020 project. 

Publications :

  1. Girum KB, Cottereau AS, Vercellino L, Rebaud L, Clerc J, Casasnovas O, Morschhauser F, Thieblemont C, Buvat I. Tumor location relative to the spleen is a prognostic factor in lymphoma patients: a demonstration from the REMARC trial. J Nucl Med, 65(2):313-319, 2024. DOI: 10.2967/jnumed.123.266322

  2. Cottereau AS , Rebaud L , Trotman J , Feugier P, Nastoupil LJ , Bachy E, Flinn IW, Haioun C,  Ysebaert L, Bartlett NL, Tilly H, Casasnovas O, Ricci R, Portugues C, Buvat I, Meignan M, Morschhauser F. Metabolic tumor volume predicts outcome in advanced stage follicular lymphoma patients from the Relevance trial. Ann Oncol, 35:130-137, 2024. DOI: https://doi.org/10.1016/j.annonc.2023.10.121

  3. Boellaard R*, Buvat I*, Nioche C, Ceriani L, Cottereau AS, Guerra L, Hicks RJ, Kanoun S, Kobe C, Loft A, Schöder H, Versari A, Coltin CA, Zwezerijnen GJC, Zijlstra JM, Mikhaeel NG, Gallamini A, El-Galaly TC, Hanoun C, Chauvie S, Ricci R, Zucca E, Meignan M, Barrington SF. International benchmark for total metabolic tumor volume measurement in baseline 18F-FDG PET/CT of lymphoma patients: a milestone towards clinical implementation. J Nucl Med, 65:1343-1348, 2024. DOI: 10.2967/jnumed.124.267789.

  4. Nanni C, Kobe C, Baessler B, Baues C, Boellaard R, Borchmann P, Buck A, Buvat I, Chapuy B, Cheson B, Chrzan R, Cottereau AS, Dührsen U, Eikenes L, Hutchings M, Jurczak W, Kraeber-Bodéré F, Kopci E, Luminari S, MacLennan S, Mikhaeel G, Nijland M, Rodriguez-Otero P, Treglia G, Withofs N, Zamagni E, Zinzani PL, Zijlstra JM, Herrmann K, Kunikowska J. EANM Focus 4: Consensus on molecular imaging and therapy in haematological tumors. Lancet Haematol, 10(5):e367-e381, 2023. DOI: 10.1016/S2352-3026(23)00030-3

  5. Girum KB, Rebaud L, Cottereau AS, Meignan M, Clerc J, Vercellino L, Casasnovas O, Morschhauser F, Thieblemont C, Buvat I. 18F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients. J Nucl Med 63(12):1925-1932, 2022. DOI :10.2967/jnumed.121.263501.

  6. Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Nizzoli M, Ciavarella S, Vegliante M, Nioche C, Meignan M, Merli F, Versari A, Ciarrocchi A, Buvat I, Luminari S. Prognostic value of lesion dissemination in ABVD-treated, iPET-negative cHL patients: a radio-genomic study. Hemat Oncol. 40(4):645-657, 2022. DOI: 10.1002/hon.3025

  7. Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I. Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. Ann Oncol. 32: 404-411, 2021. DOI: 10.1016/j.annonc.2020.11.019

  8. Cottereau AS, Meignan M, Nioche C, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I. New approaches in characterisation of lesions dissemination in DLBCL patients on baseline PET/CT. Cancers. 13:3998, 2021. DOI: https://doi.org/10.3390/cancers13163998 

  9. Capobianco N, Meignan M, Cottereau AS, Vercellino L, Sibille L, Spottiswoode B, Zuehlsdorff S, Casasnovas O, Thieblemont C, Buvat I. Deep learning FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma. J Nucl Med. 62: 30-36, 2021. DOI: 10.2967/jnumed.120.242412
  10. Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, Meignan MA, Buvat I. 18F-FDG-PET dissemination features in diffuse large B cell lymphoma are predictive of outcome. J Nucl Med. 61. 40-45, 2020. DOI: 10.2967/jnumed.119.229450